Riding the wave of the smallpox fear. Company has good financials with $1B cash on hand and in a good position to receive government funding, grants, media attention and so on

Novavax is well-positioned to capitalize on the monkeypox outbreak with its proven vaccine platform, strong financial position, and potential for government funding. The stock is currently undervalued, presenting a substantial growth opportunity as the company moves into new vaccine markets.